Het mysterie van lyme

De voortbrenger van de ziekte van Lyme geeft haar geheimen niet prijs. Feit is dat veel patiënten met symptomen blijven zitten en dat de lymebacterie goed uitgerust is om in het lichaam te 'persisteren'. Toch is het moeilijk te bewijzen wat op het eerste gezicht zo vanzelfsprekend lijkt: dat die symptomen effectief veroorzaakt worden door persisterende bacteriën. Precies die paradox wordt in dit artikel uitgespit. Als appendix bespreken we het potentieel van fytotherapie.

Beste bezoeker, u heeft geen toegang.

Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.

U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!

Auteur

Joost Meeusen

Trefwoorden:

Verschenen in

Referenties

  1. Glauser W. Combatting Lyme disease myths and the “chronic Lyme industry”. CMAJ. 2019; 191(40):E1111-E1112.
  2. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with lyme disease. Clin Infect Dis. 2007; 45(2):149-57.
  3. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014; 12(9):1103-35.
  4. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. N Engl J Med. 2016; 374(13):1209-20.
  5. Meeusen J. Moe van lyme? Kroniek van een slepende oorlog. Voedingsgeneeskunde. 2017; 18(3):24-26.
  6. Melia MT, Auwaerter PG. Time for a Different Approach to Lyme Disease and Long-Term Symptoms. N Engl J Med. 2016; 374(13):1277-8.
  7. Auwaerter PG, Melia MT. Bullying Borrelia: when the culture of science is under attack. Trans Am Clin Climatol Assoc. 2012; 123:79-89; discussion 89-90.
  8. Lantos PM. Chronic Lyme disease: the controversies and the science. Expert Rev Anti Infect Ther. 2011; 9(7):787-97.
  9. Weitzner E, McKenna D, Nowakowski J, et al. Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease. Clin Infect Dis. 2015; 61(12):1800-6.
  10. Bobe JR, Jutras BL, Horn EJ, et al. Recent Progress in Lyme Disease and Remaining Challenges. Front Med (Lausanne). 2021 Aug 18;8:666554.
  11. Eliassen KE, Hjetland R, Reiso H, et al. Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand J Prim Health Care. 2017; 35(1):75-83.
  12. Stupica D, Velušcek M, Blagus R, et al. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. J Antimicrob Chemother. 2018 May 1;73(5):1352-1358.
  13. Eliassen KE, Reiso H, Berild D, et al. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect. 2018 Dec;24(12):1290-1296.
  14. Nilsson K, Skoog E, Jones V, et al. A comprehensive clinical and laboratory evaluation of 224 patients with persistent symptoms attributed to presumed tick-bite exposure. PLoS One. 2021 Mar 18;16(3):e0247384.
  15. Bamm VV, Ko JT, Mainprize IL, et al. Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums. Pathogens. 2019 Dec 16;8(4):299.
  16. Hodzic E, Imai D, Feng S, et al. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice. PLoS One. 2014 Jan 23;9(1):e86907.
  17. Embers ME, Barthold SW, Borda JT, et al. Persistence of Borrelia burgdorferi in Rhesus macaques following antibiotic treatment of disseminated infection. PloS One. 2012;7(1):e29914.
  18. Embers ME, Hasenkampf NR, Jacobs MB, et al. Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS One. 2017 Dec 13;12(12):e0189071.
  19. Wormser GP, O'Connell S, Pachner AR, et al. Critical analysis of a doxycycline treatment trial of rhesus macaques infected with Borrelia burgdorferi. Diagn Microbiol Infect Dis. 2018 Nov;92(3):183-188.
  20. Marques A, Telford SR 3rd, Turk SP, et al. Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study. Clin Infect Dis. 2014 Apr;58(7):937-45.
  21. Rudenko N, Golovchenko M, Vancova M, et al. Isolation of live Borrelia burgdorferi sensu lato spirochaetes from patients with undefined disorders and symptoms not typical for Lyme borreliosis. Clin Microbiol Infect. 2016 Mar;22(3):267.e9-15.
  22. Sapi E, Kasliwala RS, Ismail H, et al. The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease. Antibiotics (Basel). 2019 Oct 11;8(4):183.
  23. Middelveen MJ, Sapi E, Burke J, et al. Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease. Healthcare (Basel). 2018 Apr 14;6(2):33.
  24. Middelveen MJ, Stricker RB. Morgellons disease: a filamentous borrelial dermatitis. Int J Gen Med. 2016 Oct 14;9:349-354.
  25. Wormser GP, Baker PJ, O'Connell S, et al. Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design. Vector Borne Zoonotic Dis. 2012 Jul;12(7):535-8.
  26. Marques AR, Strle F, Wormser GP. Comparison of Lyme Disease in the United States and Europe. Emerg Infect Dis. 2021 Aug;27(8):2017-2024.
  27. Patrick DM, Miller RR, Gardy JL, et al. Complex Chronic Disease Study Group. Lyme Disease Diagnosed by Alternative Methods: A Phenotype Similar to That of Chronic Fatigue Syndrome. Clin Infect Dis. 2015 Oct 1;61(7):1084-91.
  28. Shapiro ED, Baker PJ, Wormser GP. False and Misleading Information About Lyme Disease. Am J Med. 2017 Jul;130(7):771-772.
  29. Gocko X, Tattevin P, Lemogne C. Genesis and dissemination of a controversial disease: Chronic Lyme. Infect Dis Now. 2021 Feb;51(1):86-89.
  30. van Middendorp H, Berende A, Vos FJ, et al. Expectancies as predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease. Clin Rheumatol. 2021; 40(10):4295-4308.
  31. Feng J, Leone J, Schweig S, et al. Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of B. burgdorferi. Front Med (Lausanne). 2020 Feb 21;7:6.
  32. Feng J, Zhang S, Shi W, et al. Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia burgdorferi. Front Med (Lausanne). 2017 Oct 11;4:169.
  33. Feng J, Shi W, Miklossy J, et al. Identification of Essential Oils with Strong Activity against Stationary Phase Borrelia burgdorferi. Antibiotics (Basel). 2018 Oct 16;7(4):89.

Gerelateerde artikelen

Fytonutriënten bij auto-immuunziekten
Resveratrol voor een goede nierwerking
Roomse Kamille
Plantenstoffen in de strijd tegen bacteriële infecties
Moe van lyme?
Bromelaïne, het ananasenzym